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Integrated and continuously operating processes for recombinant protein drugs that rely on non-mammalian 
hosts offer potential advantages compared to CHO-based platforms for the rapid production of high-quality 
biopharmaceuticals.  This talk will describe insights and technical advances related to the realization of 
microbial-based production of proteins gained over the past four years in developing a small prototype system 
for on-demand production of biologics (Figure).   
 
Key learnings discussed will include: 1) how deep ‘-omic level’ understanding of a minimal yeast genome can 
inform both strain engineering and defined media formulation for enhanced production; 2) new platformable 
approaches for rapid in silico identification of downstream processes that provide highly orthogonal host-related 
impurity selectivity between individual chromatographic steps; and 3) examples of integration of these elements 
to enable hands-free production over days with only minor system changes required to accommodate multiple 
products.   
 
In total, holistic design principles and integration of knowledge together facilitate rapid process development and 
speed to production at scales relevant for a variety of use cases.  These examples highlight the opportunities for 
employing well-defined alternative hosts with tractable genomes in efficient integrated processes for agile 
manufacturing.  Such strategies should complement on-going and existing efforts to convert CHO-based 
platforms into continuous operations.   
 
 
 
 
Figure.  Non-platformed protein drugs produced by integrated manufacturing with microbial hosts.  Examples of 
three non-platform products produced by Pichia pastoris and purified using new approaches determined for 
purification using in silico methods. 
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